Cargando…
Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors
Adrenocortical carcinomas (ACC) are rare endocrine malignancies, often with a poor prognosis. Visfatin/NAMPT regulates a variety of signaling pathway components, and its overexpression has been found in carcinogenesis. Our study aimed to assess the clinical usefulness of visfatin/NAMPT serum level i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572558/ https://www.ncbi.nlm.nih.gov/pubmed/36233428 http://dx.doi.org/10.3390/jcm11195563 |
_version_ | 1784810645183528960 |
---|---|
author | Sawicka-Gutaj, Nadia Komarowska, Hanna Gruszczyński, Dawid Derwich, Aleksandra Klimont, Anna Ruchała, Marek |
author_facet | Sawicka-Gutaj, Nadia Komarowska, Hanna Gruszczyński, Dawid Derwich, Aleksandra Klimont, Anna Ruchała, Marek |
author_sort | Sawicka-Gutaj, Nadia |
collection | PubMed |
description | Adrenocortical carcinomas (ACC) are rare endocrine malignancies, often with a poor prognosis. Visfatin/NAMPT regulates a variety of signaling pathway components, and its overexpression has been found in carcinogenesis. Our study aimed to assess the clinical usefulness of visfatin/NAMPT serum level in discriminating between ACC and benign adrenocortical tumors. Twenty-two patients with ACC and twenty-six patients with benign adrenocortical tumors were recruited. Fasting blood samples were collected from each patient, and visfatin serum levels were measured with the ELISA Kit. Clinical stage, tumor size, Ki67 proliferation index, hormonal secretion pattern, and follow-up were determined in ACC patients. Patients with ACC had significantly higher visfatin serum concentrations (7.81 ± 2.25 vs. 6.08 ± 1.32 ng/mL, p-value = 0.003). The most advanced clinical stage with metastases was associated with significantly elevated visfatin levels (p-value = 0.022). Based on ROC analysis, visfatin serum concentrations higher than 8.05 ng/mL could discriminate ACC with a sensitivity of 50.0% and specificity of 92.3%. Univariate Cox regression indicated that tumor size was significantly related to shorter survival, and the visfatin level was borderline significant in all patients (HR = 1.013, p-value = 0.002, HR = 1.321, p-value = 0.058). In the Kaplan-Meier method, patients with visfatin serum concentrations higher than 6.3 ng/mL presented significantly lower survival probability (p-value = 0.006). Serum visfatin/NAMPT could be a potential risk predictor for the malignancy of adrenal tumors. However, further studies are needed on this subject. |
format | Online Article Text |
id | pubmed-9572558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95725582022-10-17 Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors Sawicka-Gutaj, Nadia Komarowska, Hanna Gruszczyński, Dawid Derwich, Aleksandra Klimont, Anna Ruchała, Marek J Clin Med Article Adrenocortical carcinomas (ACC) are rare endocrine malignancies, often with a poor prognosis. Visfatin/NAMPT regulates a variety of signaling pathway components, and its overexpression has been found in carcinogenesis. Our study aimed to assess the clinical usefulness of visfatin/NAMPT serum level in discriminating between ACC and benign adrenocortical tumors. Twenty-two patients with ACC and twenty-six patients with benign adrenocortical tumors were recruited. Fasting blood samples were collected from each patient, and visfatin serum levels were measured with the ELISA Kit. Clinical stage, tumor size, Ki67 proliferation index, hormonal secretion pattern, and follow-up were determined in ACC patients. Patients with ACC had significantly higher visfatin serum concentrations (7.81 ± 2.25 vs. 6.08 ± 1.32 ng/mL, p-value = 0.003). The most advanced clinical stage with metastases was associated with significantly elevated visfatin levels (p-value = 0.022). Based on ROC analysis, visfatin serum concentrations higher than 8.05 ng/mL could discriminate ACC with a sensitivity of 50.0% and specificity of 92.3%. Univariate Cox regression indicated that tumor size was significantly related to shorter survival, and the visfatin level was borderline significant in all patients (HR = 1.013, p-value = 0.002, HR = 1.321, p-value = 0.058). In the Kaplan-Meier method, patients with visfatin serum concentrations higher than 6.3 ng/mL presented significantly lower survival probability (p-value = 0.006). Serum visfatin/NAMPT could be a potential risk predictor for the malignancy of adrenal tumors. However, further studies are needed on this subject. MDPI 2022-09-22 /pmc/articles/PMC9572558/ /pubmed/36233428 http://dx.doi.org/10.3390/jcm11195563 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sawicka-Gutaj, Nadia Komarowska, Hanna Gruszczyński, Dawid Derwich, Aleksandra Klimont, Anna Ruchała, Marek Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors |
title | Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors |
title_full | Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors |
title_fullStr | Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors |
title_full_unstemmed | Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors |
title_short | Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors |
title_sort | serum visfatin/nampt as a potential risk predictor for malignancy of adrenal tumors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572558/ https://www.ncbi.nlm.nih.gov/pubmed/36233428 http://dx.doi.org/10.3390/jcm11195563 |
work_keys_str_mv | AT sawickagutajnadia serumvisfatinnamptasapotentialriskpredictorformalignancyofadrenaltumors AT komarowskahanna serumvisfatinnamptasapotentialriskpredictorformalignancyofadrenaltumors AT gruszczynskidawid serumvisfatinnamptasapotentialriskpredictorformalignancyofadrenaltumors AT derwichaleksandra serumvisfatinnamptasapotentialriskpredictorformalignancyofadrenaltumors AT klimontanna serumvisfatinnamptasapotentialriskpredictorformalignancyofadrenaltumors AT ruchałamarek serumvisfatinnamptasapotentialriskpredictorformalignancyofadrenaltumors |